{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:39:55Z","timestamp":1783561195736,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["R01 DA017302"],"award-info":[{"award-number":["R01 DA017302"]}]},{"name":"National Institute of Health","award":["DA036802"],"award-info":[{"award-number":["DA036802"]}]},{"name":"National Institute of Health","award":["P30DA013429"],"award-info":[{"award-number":["P30DA013429"]}]},{"name":"National Institute of Health","award":["DA018832"],"award-info":[{"award-number":["DA018832"]}]},{"name":"National Institute of Health","award":["DA023924"],"award-info":[{"award-number":["DA023924"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.neulet.2016.01.017","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T03:40:35Z","timestamp":1452915635000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests"],"prefix":"10.1016","volume":"615","author":[{"given":"Peng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Yakovleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane V.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5206-9497","authenticated-orcid":false,"given":"Lee-Yuan","family":"Liu-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2016.01.017_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2016.01.017_bib0010","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.neulet.2016.01.017_bib0015","first-page":"563","article-title":"Differential effects of mu and kappa opioid systems on motivational processes","volume":"75","author":"Shippenberg","year":"1986","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neulet.2016.01.017_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van\u2019t Veer","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neulet.2016.01.017_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/aps.2015.32","article-title":"The role of the dynorphin\/kappa opioid receptor system in anxiety","volume":"36","author":"Hang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neulet.2016.01.017_bib0030","doi-asserted-by":"crossref","first-page":"E704","DOI":"10.1208\/aapsj070371","article-title":"Kappa opioid antagonists: past successes and future prospects","volume":"7","author":"Metcalf","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.neulet.2016.01.017_bib0035","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1021\/jm050105i","article-title":"[Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the address domain is a novel kappa-opioid receptor antagonist","volume":"48","author":"Patkar","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neulet.2016.01.017_bib0040","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.0910180106","article-title":"Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action","volume":"106","author":"Aldrich","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2016.01.017_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2011.04.017","article-title":"Identification of short-acting kappa-opioid receptor antagonists with anxiolytic-like activity","volume":"661","author":"Peters","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2016.01.017_bib0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2015.05.023","article-title":"Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice","volume":"97","author":"Jackson","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2016.01.017_bib0055","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/jm200789r","article-title":"Discovery of aminobenzyloxyarylamides as kappa opioid receptor selective antagonists: application to preclinical development of a kappa opioid receptor antagonist receptor occupancy tracer","volume":"54","author":"Mitch","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neulet.2016.01.017_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neubiorev.2005.03.017","article-title":"Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test","volume":"29","author":"Dulawa","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neulet.2016.01.017_bib0065","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/npp.2008.234","article-title":"Enhanced sensitivity of the MRL\/MpJ mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments","volume":"34","author":"Balu","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2016.01.017_bib0070","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/npp.2010.234","article-title":"Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect","volume":"36","author":"Onksen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2016.01.017_bib0075","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neulet.2010.03.071","article-title":"Anxiety-like effects of 141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze","volume":"475","author":"Huang","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2016.01.017_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0091-3057(95)02126-4","article-title":"A review of the validity and variability of the elevated plus-maze as an animal model of anxiety","volume":"54","author":"Hogg","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2016.01.017_bib0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-4328(01)00292-3","article-title":"Factors controlling measures of anxiety and responses to novelty in the mouse","volume":"125","author":"File","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neulet.2016.01.017_bib0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/jpet.106.101287","article-title":"Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling","volume":"318","author":"Patel","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2016.01.017_bib0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.drugalcdep.2013.08.021","article-title":"l-Isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors","volume":"133","author":"Xu","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neulet.2016.01.017_bib0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-010-1803-1","article-title":"Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse","volume":"210","author":"Jackson","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neulet.2016.01.017_bib0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.111.185108","article-title":"Pharmacological characterization of 2-methyl-N-((2\u2032-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa-opioid receptors","volume":"339","author":"Grimwood","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2016.01.017_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2016.01.017_bib0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neulet.2014.01.022","article-title":"Zyklophin a short-acting kappa opioid antagonist, induces scratching in mice","volume":"563","author":"DiMattio","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2016.01.017_bib0120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.neulet.2016.01.017_bib0125","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neulet.2016.01.017_bib0130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-3565(25)11434-1","article-title":"Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test","volume":"260","author":"Horan","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2016.01.017_bib0135","doi-asserted-by":"crossref","first-page":"29803","DOI":"10.1074\/jbc.M705540200","article-title":"Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase","volume":"282","author":"Bruchas","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2016.01.017_bib0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/mol.111.074195","article-title":"Duration of action of a broad range of selective kappa-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation","volume":"80","author":"Melief","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neulet.2016.01.017_bib0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-12-5","article-title":"Long-acting kappa opioid antagonists nor-BNI GNTI and JDTic: pharmacokinetics in mice and lipophilicity","volume":"12","author":"Munro","year":"2012","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.neulet.2016.01.017_bib0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1124\/jpet.113.206086","article-title":"Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on kappa-opioid receptors","volume":"346","author":"Patkar","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2016.01.017_bib0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2013.07.040","article-title":"Pharmacokinetic evidence for the long-lasting effect of nor-binaltorphimine a potent kappa opioid receptor antagonist, in mice","volume":"552","author":"Kishioka","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2016.01.017_bib0160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394016300179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394016300179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:31:38Z","timestamp":1748752298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394016300179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":32,"alternative-id":["S0304394016300179"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2016.01.017","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2016.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}